Daraxonrasib

1 article

Doctor and patient share a moment of hope as a new pancreatic cancer drug shows promising survival rate increases in clinical trials.

New Pancreatic Cancer Drug Daraxonrasib Nearly Doubles Survival

In a groundbreaking Phase 3 trial, an experimental drug nearly doubled the median overall survival for patients with advanced pancreatic cancer, a disease notoriously resistant to treatment.

Caitlin O'Malley·May 31, 2026